{"id":"W4399926566","doi":"10.1016/j.esmoop.2024.103539","title":"39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Daiichi Sankyo Europe; LEO Pharma; Eisai; Cilag; Novocure; Astellas Pharma; Clovis Oncology; Amgen; Pfizer; MorphoSys; PharmaMar; Mersana Therapeutics; Fujirebio US; AstraZeneca; Eli Lilly and Company","keywords":"Pembrolizumab; Lenvatinib; Medicine; Oncology; Chemotherapy; Internal medicine; Endometrial cancer; Gynecology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001744075,0.00140139,0.00131299,0.0002546971,0.0003102423,0.0009827188,0.0008024532,0.001431794,0.008977009],"category_scores_gemma":[0.0007143159,0.0004537416,0.001474142,0.0002146862,0.0004435192,0.0005571954,0.0004260718,0.002938593,0.001823446],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008540754,"about_ca_system_score_gemma":0.00112852,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008517644,"about_ca_topic_score_gemma":0.002933586,"domain_scores_codex":[0.9996746,0.000196946,0.000009276931,0.00004071959,0.00002587083,0.00005266356],"domain_scores_gemma":[0.9996399,0.00007578504,0.00007185681,0.00002516978,0.00002241086,0.0001648756],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9061764,0.02333819,0.00206469,0.0009864458,0.001237256,0.0001261626,0.00009789434,0.001440908,0.01355356,0.0005120777,0.007711052,0.04275547],"study_design_scores_gemma":[0.800159,0.1773685,0.00631096,0.0001246589,0.0007834976,0.00016806,0.00005346254,0.001460506,0.001938787,0.0005729229,0.01102831,0.00003130441],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9615899,0.006447068,0.001129195,0.001775119,0.000629577,0.007964905,0.009915477,0.0002297811,0.01031901],"genre_scores_gemma":[0.9420249,0.00487019,0.004126575,0.004116457,0.0004059745,0.01066059,0.01157762,0.0001244443,0.02209318],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008977009,"threshold_uncertainty_score":0.03003103,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08448183385298305,"score_gpt":0.4378377915686064,"score_spread":0.3533559577156233,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}